[{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","commit":"ad64caf371","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fifth batch of approved products","file":"src/data/spikes/neuroendocrine.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sunitinib\" }]"}]},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"management"},{"field":"food"},{"field":"source"}]},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"cancers"},{"field":"setting"},{"field":"intent"},{"field":"cycleDays"},{"field":"cycles"},{"field":"components"},{"field":"emetogenicity"},{"field":"gcsf"},{"field":"trials"},{"field":"source"},{"field":"asOf"}]},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/neuroendocrine.ts","type":"changed","fields":[{"field":"tldr","before":"\"An anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.\"","after":"\"Sunitinib is an anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.\""}]},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","commit":"06611b41fb","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: SCLC, mesothelioma, urothelial, RCC deep dives with structured outcomes, dosing, toxicity, regulatory events","file":"src/data/spikes/rcc.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, toxicity, regulatory","file":"src/data/spikes/neuroendocrine.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"}]}]